Japanese data confirm triglyceride benefits for Takeda/ProNova's omega-3 product
This article was originally published in Scrip
Executive Summary
Takeda and licensor ProNova BioPharma have released further details of a Japanese Phase III trial with their fish oil-derived prescription drug for triglyceride disorders which looks set to strengthen its direct competitive position opposite Mochida's top selling product Epadel once it reaches the market.